Novavax (NVAX) Net Income Growth (3y) (2013 - 2026)
Novavax (NVAX) Net Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 9.16% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 79.26% |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 47.10% |
| 10 | Novavax | 1.24 Bn | 453.01 Mn | 108.82 Mn | 68.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.16% |
| Dec 31, 2025 | 27.98% |
| Sep 30, 2025 | -6.27% |
| Jun 30, 2025 | 30.23% |
| Mar 31, 2025 | 36.62% |
| Dec 31, 2024 | 54.25% |
| Sep 30, 2024 | 27.81% |
| Jun 30, 2024 | 35.01% |
| Mar 31, 2024 | 12.82% |
| Dec 31, 2023 | -0.15% |
| Sep 30, 2023 | 12.81% |
| Jun 30, 2023 | 74.47% |
| Mar 31, 2023 | -124.82% |
| Dec 31, 2022 | -81.65% |
| Sep 30, 2022 | -110.61% |
| Jun 30, 2022 | -134.48% |
| Mar 31, 2022 | 88.59% |
| Dec 31, 2021 | -160.44% |
| Sep 30, 2021 | -93.43% |
| Jun 30, 2021 | -99.18% |